Fragment-based drug discovery using NMR spectroscopy

Journal of Biomolecular NMR

Volumn 56, Issue 2, 2013, Pages 65-75

  Harner, Mary J ^a   Frank, Andreas O ^a,b   Fesik, Stephen W ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

Fragment libraries; Fragment based drug discovery; Fragment based screening; Hit identification; NMR spectroscopy

Indexed keywords

CARBOXYLIC ACID; HYDROXYLAMINE;

AQUEOUS SOLUTION; BINDING AFFINITY; BINDING KINETICS; BINDING SITE; BIOLOGICAL MONITORING; DIFFUSION; DRUG DESIGN; DRUG RESEARCH; DRUG SCREENING; FLUORESCENCE POLARIZATION; FOLLOW UP; HYDROGEN BOND; HYDROPHOBICITY; LIGAND BINDING; MAGNETIC FIELD; MOLECULAR INTERACTION; MOLECULAR LIBRARY; MOLECULAR WEIGHT; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; NUCLEAR OVERHAUSER EFFECT; POLARIZATION; PRACTICE GUIDELINE; PRECIPITATION; PRIORITY JOURNAL; PROTEIN ENGINEERING; REVIEW; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY;

DRUG DISCOVERY; LIGANDS; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; PROTEIN BINDING; PROTEINS; SMALL MOLECULE LIBRARIES;

EID: 84879844246     PISSN: 09252738     EISSN: 15735001     Source Type: Journal    
DOI: 10.1007/s10858-013-9740-z     Document Type: Review

References (76)

1. Baell JB (2010) Observations on screening-based research and some concerning trends in the literature. Future Med Chem 2:1529-1546
2. Baell JB, Holloway GA (2010) New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. J Med Chem 53:2719-2740
3. Becattini B, Pellecchia M (2006) SAR by ILOEs: an NMR-based approach to reverse chemical genetics. Chemistry 12:2658-2662
4. Becattini B, Culmsee C, Leone M, Zhai D, Zhang X, Crowell KJ, Rega MF, Landshamer S, Reed JC, Plesnila N et al (2006) Structure-activity relationships by interligand NOE-based design and synthesis of antiapoptotic compounds targeting Bid. Proc Natl Acad Sci USA 103:12602-12606
5. Bohm HJ, Florh A, Stahl M (2004) Scaffold hopping. Drug Discov Today 1:217-224
6. Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, Cho H, Spevak W, Zhang C, Zhang Y, Habets G et al (2010) Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467:596-599
7. Borsi V, Calderone V, Fragai M, Luchinat C, Sarti N (2010) Entropic contribution to the linking coefficient in fragment based drug design: a case study. J Med Chem 53:4285-4289
8. Bottcher J, Jestel A, Kiefersauer R, Krapp S, Nagel S, Steinbacher S, Steuber H (2011) Key factors for successful generation of protein-fragment structures requirement on protein, crystals, and technology. Meth Enzymol 493:61-89
9. Campos-Olivas R (2011) NMR screening and hit validation in fragment based drug discovery. Curr Top Med Chem 11:43-67
10. Carr RA, Congreve M, Murray CW, Rees DC (2005) Fragment-based lead discovery: leads by design. Drug Discov Today 10:987-992
11. Chessari G, Woodhead AJ (2009) From fragment to clinical candidate-a historical perspective. Drug Discov Today 14:668-675
12. Chung S, Parker JB, Bianchet M, Amzel LM, Stivers JT (2009) Impact of linker strain and flexibility in the design of a fragment-based inhibitor. Nat Chem Biol 5:407-413
13. Cioffi M, Hunter CA, Packer MJ, Spitaleri A (2008) Determination of protein-ligand binding modes using complexation-induced changes in (1)h NMR chemical shift. J Med Chem 51:2512-2517
14. Congreve M, Carr R, Murray C, Jhoti H (2003) A 'rule of three' for fragment-based lead discovery? Drug Discov Today 8:876-877
15. Constantine KL, Davis ME, Metzler WJ, Mueller L, Claus BL (2006) Protein-ligand NOE matching: a high-throughput method for binding pose evaluation that does not require protein NMR resonance assignments. J Am Chem Soc 128:7252-7263
16. Dalvit C (2009) NMR methods in fragment screening: theory and a comparison with other biophysical techniques. Drug Discov Today 14:1051-1057
17. Dalvit C, Pevarello P, Tato M, Veronesi M, Vulpetti A, Sundstrom M (2000) Identification of compounds with binding affinity to proteins via magnetization transfer from bulk water. J Biomol NMR 18:65-68
18. Dalvit C, Flocco M, Veronesi M, Stockman BJ (2002) Fluorine-NMR competition binding experiments for high-throughput screening of large compound mixtures. Comb Chem High Throughput Screen 5:605-611
19. Erlanson DA (2006) Fragment-based lead discovery: a chemical update. Curr Opin Biotechnol 17:643-652
20. Erlanson DA, Wells JA, Braisted AC (2004) Tethering: fragment-based drug discovery. Annu Rev Biophys Biomol Struct 33:199-223
21. Felli IC, Brutscher B (2009) Recent advances in solution NMR: fast methods and heteronuclear direct detection. Chem Phys Chem 10:1356-1368
22. Feng BY, Shelat A, Doman TN, Guy RK, Shoichet BK (2005) High-throughput assays for promiscuous inhibitors. Nat Chem Biol 1:146-148
23. Fernandez C, Jahnke W (2004) New approaches for NMR screening in drug discovery. Drg Discov Today 1:277-283
24. Fielding L (2007) NMR methods for the determination of protein-ligand dissociation constants. Prog NMR Spec 51:219-242
25. Friberg A, Vigil D, Zhao B, Daniels RN, Burke JP, Garcia-Barrantes PM, Camper D, Chauder BA, Lee T, Olejniczak ET et al (2013) Discovery of potent myeloid cell leukemia 1 (mcl-1) inhibitors using fragment-based methods and structure-based design. J Med Chem 56:15-30
26. Guntert P (2009) Automated structure determination from NMR spectra. Eur Biophys J 38:129-143
27. Hajduk PJ, Greer J (2007) A decade of fragment-based drug design: strategic advances and lessons learned. Nat Rev Drug Discov 6:211-219
28. Hajduk PJ, Meadows RP, Fesik SW (1997) Discovering high-affinity ligands for proteins. Science 278(497):499
29. Hajduk PJ, Augeri DJ, Mack J, Mendoza R, Yang J, Betz SF, Fesik SW (2000a) NMR-based screening of proteins containing 13C-labeled methyl groups. J Am Chem Soc 122:7898-7904
30. Hajduk PJ, Bures M, Praestgaard J, Fesik SW (2000b) Privileged molecules for protein binding identified from NMR-based screening. J Med Chem 43:3443-3447
31. Hajduk PJ, Mack JC, Olejniczak ET, Park C, Dandliker PJ, Beutel BA (2004) SOS-NMR: a saturation transfer NMR-based method for determining the structures of protein-ligand complexes. J Am Chem Soc 126:2390-2398
32. Hoffer L, Renaud JP, Horvath D (2011) Fragment-based drug design: computational & experimental state of the art. Comb Chem High Throughput Screen 14:500-520
33. Hopkins AL, Groom CR (2002) The druggable genome. Nat Rev Drug Discov 1:727-730
34. Hopkins AL, Groom CR, Alex A (2004) Ligand efficiency: a useful metric for lead selection. Drug Discov Today 9:430-431
35. Hung AW, Silvestre HL, Wen S, Ciulli A, Blundell TL, Abell C (2009) Application of fragment growing and fragment linking to the discovery of inhibitors of Mycobacterium tuberculosis pantothenate synthetase. Angew Chem Int Ed Engl 48:8452-8456
36. Huth JR, Mendoza R, Olejniczak ET, Johnson RW, Cothron DA, Liu Y, Lerner CG, Chen J, Hajduk PJ (2005) ALARM NMR: a rapid and robust experimental method to detect reactive false positives in biochemical screens. J Am Chem Soc 127:217-224
37. Ichihara O, Barker J, Law RJ, Whittaker M (2011) Compound design by fragment-linking. Mol Inf 30:298-306
38. Jahnke W (2002) Spin labels as a tool to identify and characterize protein-ligand interactions by NMR spectroscopy. Chem Bio Chem 3:167-173
39. Jahnke W, Florsheimer A, Blommers MJ, Paris CG, Heim J, Nalin CM, Perez LB (2003) Second-site NMR screening and linker design. Curr Top Med Chem 3:69-80
40. Jencks WP (1981) On the attribution and additivity of binding energies. Proc Natl Acad Sci USA 78:4046-4050
41. Jhoti H, Cleasby A, Verdonk M, Williams G (2007) Fragment-based screening using X-ray crystallography and NMR spectroscopy. Curr Opin Chem Biol 11:485-493
42. Klages J, Coles M, Kessler H (2007) NMR-based screening: a powerful tool in fragment-based drug discovery. Analyst 132:693-705
43. Kohlmann A, Zech SG, Li F, Zhou T, Squillace RM, Commodore L, Greenfield MT, Lu X, Miller DP, Huang WS et al (2013) Fragment growing and linking lead to novel nanomolar lactate dehydrogenase inhibitors. J Med Chem
44. Krimm I (2012) INPHARMA-based identification of ligand binding site in fragment-based drug design. Med Chem Comm 3:605-610
45. Krishnamoorthy J, Yu VC, Mok YK (2010) Auto-FACE: an NMR based binding site mapping program for fast chemical exchange protein-ligand systems. PLoS One 5:e8943
46. Kuntz ID, Chen K, Sharp KA, Kollman PA (1999) The maximal affinity of ligands. Proc Natl Acad Sci USA 96:9997-10002
47. Leone M, Freeze HH, Chan CS, Pellecchia M (2006) The Nuclear Overhauser Effect in the lead identification process. Curr Drug Discov Technol 3:91-100
48. Lepre CA (2011) Practical aspects of NMR-based fragment screening. Meth Enzymol 493:219-239
49. Lescop E, Kern T, Brutscher B (2010) Guidelines for the use of band-selective radiofrequency pulses in hetero-nuclear NMR: example of longitudinal-relaxation-enhanced BEST-type 1H-15 N correlation experiments. J Magn Reson 203:190-198
50. Li D, DeRose EF, London RE (1999) The inter-ligand Overhauser effect: a powerful new NMR approach for mapping structural relationships of macromolecular ligands. J Biomol NMR 15:71-76
51. Ludwig C, Guenther UL (2009) Ligand based NMR methods for drug discovery. Front Biosci 14:4565-4574
52. Ludwig C, Michiels PJ, Wu X, Kavanagh KL, Pilka E, Jansson A, Oppermann U, Gunther UL (2008) SALMON: solvent accessibility, ligand binding, and mapping of ligand orientation by NMR spectroscopy. J Med Chem 51:1-3
53. Manzenrieder F, Frank AO, Kessler H (2008) Phosphorus NMR spectroscopy as a versatile tool for compound library screening. Angew Chem Int Ed Engl 47:2608-2611
54. Mayer M, Meyer B (1999) Characterization of ligand binding of saturation transfer difference NMR spectroscopy. Angew Chem Int Ed Engl 38:1784-1788
55. Mayer M, Meyer B (2001) Group epitope mapping by saturation transfer difference NMR to identify segments of a ligand in direct contact with a protein receptor. J Am Chem Soc 123:6108-6117
56. McCoy MA, Wyss DF (2002) Spatial localization of ligand binding sites from electron current density surfaces calculated from NMR chemical shift perturbations. J Am Chem Soc 124:11758-11763
57. Meyer B, Peters T (2003) NMR spectroscopy techniques for screening and identifying ligand binding to protein receptors. Angew Chem Int Ed Engl 42:864-890
58. Murray CW, Blundell TL (2010) Structural biology in fragment-based drug design. Curr Opin Struct Biol 20:497-507
59. Pellecchia M, Bertini I, Cowburn D, Dalvit C, Giralt E, Jahnke W, James TL, Homans SW, Kessler H, Luchinat C et al (2008) Perspectives on NMR in drug discovery: a technique comes of age. Nat Rev Drug Discov 7:738-745
60. Pervushin K, Riek R, Wider G, Wuthrich K (1997) Attenuated T2 relaxation by mutual cancellation of dipole-dipole coupling and chemical shift anisotropy indicates an avenue to NMR structures of very large biological macromolecules in solution. Proc Natl Acad Sci USA 94:12366-12371
61. Rega MF, Wu B, Wei J, Zhang Z, Cellitti JF, Pellecchia M (2011) SAR by interligand nuclear overhauser effects (ILOEs) based discovery of acylsulfonamide compounds active against Bcl-x(L) and Mcl-1. J Med Chem 54:6000-6013
62. Reibarkh M, Malia TJ, Wagner G (2006) NMR distinction of single- and multiple-mode binding of small-molecule protein ligands. J Am Chem Soc 128:2160-2161
63. Sanchez-Pedregal VM, Reese M, Meiler J, Blommers MJ, Griesinger C, Carlomagno T (2005) The INPHARMA method: protein-mediated interligand NOEs for pharmacophore mapping. Angew Chem Int Ed Engl 44:4172-4175
64. Schanda P, Kupce E, Brutscher B (2005) SOFAST-HMQC experiments for recording two-dimensional heteronuclear correlation spectra of proteins within a few seconds. J Biomol NMR 33:199-211
65. Seidler J, McGovern SL, Doman TN, Shoichet BK (2003) Identification and prediction of promiscuous aggregating inhibitors among known drugs. J Med Chem 46:4477-4486
66. Shortridge MD, Powers R (2011) NMR Screening Methods for Drug Discovery. In: Biomolecular NMR Spectroscopy. IOS Press BV, Netherlands, p 381
67. Shuker SB, Hajduk PJ, Meadows RP, Fesik SW (1996) Discovering high-affinity ligands for proteins: SAR by NMR. Science 274:1531-1534
68. Sledz P, Silvestre HL, Hung AW, Ciulli A, Blundell TL, Abell C (2010) Optimization of the interligand Overhauser effect for fragment linking: application to inhibitor discovery against Mycobacterium tuberculosis pantothenate synthetase. J Am Chem Soc 132:4544-4545
69. Sun Q, Burke JP, Phan J, Burns MC, Olejniczak ET, Waterson AG, Lee T, Rossanese OW, Fesik SW (2012) Discovery of small molecules that bind to K-Ras and inhibit Sos-mediated activation. Angew Chem Int Ed Engl 51:6140-6143
70. Tengel T, Fex T, Emtenas H, Almqvist F, Sethson I, Kihlberg J (2004) Use of 19F NMR spectroscopy to screen chemical libraries for ligands that bind to proteins. Org Biomol Chem 2:725-731
71. Vanwetswinkel S, Heetebrij RJ, van Duynhoven J, Hollander JG, Filippov DV, Hajduk PJ, Siegal G (2005) TINS, target immobilized NMR screening: an efficient and sensitive method for ligand discovery. Chem Biol 12:207-216
72. Vazquez J, Tautz L, Ryan JJ, Vuori K, Mustelin T, Pellecchia M (2007) Development of molecular probes for second-site screening and design of protein tyrosine phosphatase inhibitors. J Med Chem 50:2137-2143
73. Vazquez J, De SK, Chen LH, Riel-Mehan M, Emdadi A, Cellitti J, Stebbins JL, Rega MF, Pellecchia M (2008) Development of paramagnetic probes for molecular recognition studies in protein kinases. J Med Chem 51:3460-3465
74. Warr WA (2011) Some trends in chem(o)informatics. Meth Mol Biol 672:1-37
75. Wu B, Zhang Z, Noberini R, Barile E, Giulianotti M, Pinilla C, Houghten RA, Pasquale EB, Pellecchia M (2013) HTS by NMR of combinatorial libraries: a fragment-based approach to ligand discovery. Chem Biol 20:19-33
76. Zhang X, Sanger A, Hemmig R, Jahnke W (2009) Ranking of high-affinity ligands by NMR spectroscopy. Angew Chem Int Ed Engl 48:6691-6694